Taysha Gene Therapies (TSHA) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 1, 2026, will be held virtually, with voting on four key proposals and other business as may arise.

• Record date for voting is April 8, 2026, with 287,341,999 shares outstanding and entitled to vote.

• Proxy materials are primarily provided online, with options for internet, phone, or mail voting.

Voting matters and shareholder proposals

• Election of two Class III directors (Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D.) to serve until the 2029 Annual Meeting.

• Ratification of Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026.

• Advisory vote on executive compensation (say-on-pay).

• Advisory vote on the frequency of future say-on-pay votes, with the Board recommending annual votes.

• Shareholders may submit proposals for the 2027 meeting by December 23, 2026, for inclusion in the proxy statement.

Board of directors and corporate governance

• Board consists of six members divided into three classes, with a mix of industry, financial, and scientific expertise.

• Four directors are independent under Nasdaq and SEC rules; CEO serves as Board Chair.

• Board has Audit, Compensation, Nominating and Corporate Governance, and Clinical and Scientific Committees.

• Board met seven times in the last fiscal year; all directors attended at least 75% of meetings.

• Code of Ethics, Insider Trading Policy, and Hedging Policy are in place for directors, officers, and employees.